Literature DB >> 25381079

Unrecognized heart failure and chronic obstructive pulmonary disease (COPD) in frail elderly detected through a near-home targeted screening strategy.

Yvonne van Mourik1, Loes C M Bertens2, Maarten J M Cramer2, Jan-Willem J Lammers2, Johannes B Reitsma2, Karel G M Moons2, Arno W Hoes2, Frans H Rutten2.   

Abstract

BACKGROUND: Reduced exercise tolerance and dyspnea are common in older people, and heart failure (HF) and chronic obstructive pulmonary disease (COPD) are the main causes. We want to determine the prevalence of previously unrecognized HF, COPD, and other chronic diseases in frail older people using a near-home targeted screening strategy.
METHODS: Community-dwelling frail persons aged ≥65 years underwent a 2-step screening strategy. First, they received a questionnaire inquiring about dyspnea and exercise tolerance. Those with exercise intolerance and/or dyspnea were invited to visit their primary care physician's office for a screening program, including medical history taking, physical examination, blood tests, electrocardiography, spirometry, and echocardiography. The final diagnosis of every patient was determined by a panel consisting of 3 physicians.
RESULTS: Of the 570 elderly who filled out the questionnaire, 395 (69%) had reduced exercise tolerance or dyspnea. Of these, 389 underwent the screening program: 127 (33.5%, 95% confidence interval, 28.9-38.4%) were newly diagnosed with HF (mainly HF with a preserved ejection fraction [23.5%]), and previously unrecognized COPD was detected in 16.8% (95% confidence interval, 13.4-20.9%). In total, 165 patients (43.9%) received a new diagnosis of either HF, COPD, or both. Other new diagnoses (in 32.7% of the screening program patients) included atrial fibrillation (1.8%), valvular disease (21.4%), (persisting) asthma (3.1%), anemia (12.7%), and thyroid disease (0.6%). No clear explanation for the complaints of 47 patients (12.2%) was found using our strategy.
CONCLUSION: Unrecognized chronic diseases might be detected in community-dwelling frail elderly using a near-home screening strategy that is simple to implement. It remains to be proven, however, whether optimizing treatment of the newly detected diagnoses in this fragile population with multimorbidities and polypharmacy improves quality of life and reduces morbidity and mortality. © Copyright 2014 by the American Board of Family Medicine.

Entities:  

Keywords:  COPD; Cardiovascular Abnormalities; Dyspnea; Exercise Tolerance; Frail Elderly; Heart Failure; Respiratory Tract Diseases

Mesh:

Year:  2014        PMID: 25381079     DOI: 10.3122/jabfm.2014.06.140045

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  12 in total

1.  Overdiagnosis of heart failure in primary care: a cross-sectional study.

Authors:  Mark J Valk; Arend Mosterd; Berna Dl Broekhuizen; Nicolaas Pa Zuithoff; Marcel Aj Landman; Arno W Hoes; Frans H Rutten
Journal:  Br J Gen Pract       Date:  2016-06-06       Impact factor: 5.386

2.  Reliability of the blood pressure response during performance of bedside Valsalva maneuver and association with NT-pBNP levels.

Authors:  J Schlitzer; H J Heppner; H Frohnhofen
Journal:  Z Gerontol Geriatr       Date:  2021-02-03       Impact factor: 1.281

3.  Does Frailty Predict Health Care Utilization in Community-Living Older Romanians?

Authors:  Marinela Olaroiu; Minerva Ghinescu; Viorica Naumov; Ileana Brinza; Wim van den Heuvel
Journal:  Curr Gerontol Geriatr Res       Date:  2016-07-17

4.  Efficient selective screening for heart failure in elderly men and women from the community: A diagnostic individual participant data meta-analysis.

Authors:  Rogier F Kievit; Aisha Gohar; Arno W Hoes; Michiel L Bots; Evelien Es van Riet; Yvonne van Mourik; Loes Cm Bertens; Leandra Jm Boonman-de Winter; Hester M den Ruijter; Frans H Rutten
Journal:  Eur J Prev Cardiol       Date:  2018-01-12       Impact factor: 7.804

5.  Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis.

Authors:  Pawel Petryszyn; Piotr Niewinski; Aleksandra Staniak; Patryk Piotrowski; Anna Well; Michal Well; Izabela Jeskowiak; Gregory Lip; Piotr Ponikowski
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

6.  Characteristics of heart failure patients incurring high medical costs via matching specific health examination results and medical claim data: a cross-sectional study.

Authors:  Yuya Tamaki; Kana Kazawa; Hirohito Watanabe; Tantut Susanto; Michiko Moriyama
Journal:  BMJ Open       Date:  2019-12-15       Impact factor: 2.692

7.  Eccentric Left Ventricular Hypertrophy and Left and Right Cardiac Function in Chronic Heart Failure with or without Coexisting COPD: Impact on Exercise Performance.

Authors:  Polliana B Dos Santos; Rodrigo P Simões; Cássia da L Goulart; Meliza G Roscani; Renan S Marinho; Patrícia Faria Camargo; Renata F Arbex; Guilherme Casale; Cláudio R Oliveira; Renata G Mendes; Ross Arena; Audrey Borghi-Silva
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-02-03

8.  Office-Based Case Finding for Chronic Obstructive Pulmonary Disease in Older Adults in Primary Care.

Authors:  Linda Lee; Tejal Patel; Loretta M Hillier; James Milligan
Journal:  Can Respir J       Date:  2016-06-22       Impact factor: 2.409

9.  Sex-specific microRNAs in women with diabetes and left ventricular diastolic dysfunction or HFpEF associate with microvascular injury.

Authors:  Barend W Florijn; Gideon B Valstar; Jacques M G J Duijs; Roxana Menken; Maarten J Cramer; Arco J Teske; Chahinda Ghossein-Doha; Frans H Rutten; Marc E A Spaanderman; Hester M den Ruijter; Roel Bijkerk; Anton Jan van Zonneveld
Journal:  Sci Rep       Date:  2020-08-18       Impact factor: 4.379

10.  Opportunistic screening models for high-risk men and women to detect diastolic dysfunction and heart failure with preserved ejection fraction in the community.

Authors:  Aisha Gohar; Rogier F Kievit; Gideon B Valstar; Arno W Hoes; Evelien E Van Riet; Yvonne van Mourik; Loes C Bertens; Leandra J Boonman-Winter; Michiel L Bots; Hester M Den Ruijter; Frans H Rutten
Journal:  Eur J Prev Cardiol       Date:  2018-11-27       Impact factor: 7.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.